1409P - Cervical cancer screening in France: recent change in behaviors

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancers in Adolescents and Young Adults (AYA)
Cervical Cancer
Aetiology, epidemiology, screening and prevention
Gynaecologic Malignancies
Basic Scientific Principles
Presenter Thibault de La Motte Rouge
Citation Annals of Oncology (2017) 28 (suppl_5): v502-v506. 10.1093/annonc/mdx383
Authors T. de La Motte Rouge1, J. Viguier2, J. Morere3, L. Brignoli-Guibaudet4, J. Blay5, C. Lhomel6, F. Eisinger7
  • 1Medical Oncology, Centre Eugene - Marquis, 35042 - Rennes/FR
  • 2Medical Oncology, CHRU Bretonneau, 37044 - Tours/FR
  • 3Medical Oncology, Hopital Paul Brousse, 94804 - Villejuif/FR
  • 4Statistics, Kantarhealth, Paris/FR
  • 5Medical Oncology, Centre Leon Berard, 69008 - Lyon/FR
  • 6Medical, Roche - France, 9265000 - Boulogne-Billancourt/FR
  • 7Aix Marseille Univ, Inserm, Sesstim, Institute Paoli Calmettes, 1300674 - Marseille/FR



Cervical cancer (CC) is the fourth most common cancer in women in France. Human papillomavirus vaccination and screening are complementary secondary prevention measures against CC. Screening by conventional Pap smear is recommended every three years for women aged 25-65y.


The EDIFICE nationwide observational surveys assess population attitudes to cancer screening in general. Representative samples of the French population aged 50-75 years are interviewed by phone using the quota method. Although the French CC screening program covers all women aged 26-65y, the present analysis pertains to a subpopulation aged 50-65y (N = 356 in 2014 and N = 460 in 2016). Interviewees, with no personal history of cancer, were asked if they had ever had a smear test during a gynecological exam. The date of the last test was noted. Data analysis focused on age group, socioprofessional categories (SPC) and social vulnerability (defined by the EPICE score).


In 2016, 94% of interviewees reported at least one lifetime smear test vs. 99% in 2014 (P


Between 2014 and 2016, participation in CC screening decreased and compliance rates stagnated. Compliance with screening recommendations was negatively affected by the following: unemployment, low SPC or classification among vulnerable populations. Additional analysis will further investigate these findings, which highlight the need for generalized population-based screening programs and targeted actions for non-participants, as advocated earlier this year by the French National Cancer Institute (INCa).

Clinical trial identification

Legal entity responsible for the study

Kantar Health




T. de la Motte Rouge: Consultancy work AstraZeneca, Roche, MSD, Eisai, Sanofi Travel Grants/meeting support Roche, Novartis, Pfizer. Corporate-sponsored research Novartis. J-F. Morere, J-Y. Blay, F. Eisinger: Honorarium fees from Roche Edifice surveys were funded by Roche S.A. C. Lhomel: Employee of Roche. All other authors have declared no conflicts of interest.